Literature DB >> 15973918

Comparative study between propofol in a long-chain triglyceride and propofol in a medium/long-chain triglyceride during sedation with target-controlled infusion.

M Yamakage1, S Iwasaki, S W Jeong, S I Ishiyama, A Namiki.   

Abstract

This study was performed to compare the pharmacological characteristics of propofol in an emulsion of both medium- and long-chain triglycerides (MCT/LCT) with those of propofol in an LCT emulsion, by measuring the sedative level and the plasma concentration of propofol during sedation using a target-controlled infusion (TCI) technique. Forty ASA 1 or 2 adult patients who required spinal anaesthesia for surgery were enrolled in this study. The patients were divided into two groups: a propofol LCT group (n = 20) and a propofol MCT/LCT group (n = 20). Propofol was injected intravenously at target blood concentrations of 2.0, 3.0 and 4.0 microg x ml(-1). The bispectral (BIS) index was recorded, and arterial blood was drawn to measure the actual plasma concentrations of propofol at each predicted concentration. Propofol was assayed by high-performance liquid chromatography. Propofol MCT/LCT was associated with significantly less pain than propofol LCT (P < 0.05). There were no significant differences between the two groups in BIS index or in plasma concentration of propofol at each predicted concentration. Computer-generated TCI of propofol MCT/LCT during sedation is comparable with that of propofol LCT with respect to pharmacokinetics and pharmacodynamics. The formulation of MCT/LCT has a beneficial effect with respect to less pain on injection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15973918     DOI: 10.1177/0310057X0503300301

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  1 in total

1.  Lornoxicam use to reduce the pain associated with propofol injection.

Authors:  Nihal Başak; Yakup Aksoy; Ayhan Kaydu; Ömer Fatih Şahin
Journal:  Libyan J Med       Date:  2017-12       Impact factor: 1.657

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.